From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 2, 2009-02 ,pp. : 221-229

Bentham Science Publishers

Access to resources Recommend Favorite

C-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells

By Gregory MacEwen E.   Kutzke Jon   Carew Jennifer   Pastor Josep   Schmidt Julie   Tsan Rachel   Thamm Douglas   Radinsky Robert  

Clinical and Experimental Metastasis, Vol. 20, Iss. 5, 2003-09 ,pp. : 421-430

Springer Publishing Company

Access to resources Recommend Favorite

An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 1, 2010-01 ,pp. : 28-35

Bentham Science Publishers

Access to resources Recommend Favorite

Tyrosylprotein sulfotransferase 1 expression is negatively correlated with cMet and lymph node metastasis in human lung cancer

By            

Molecular Medicine Reports, Vol. 12, Iss. 4, 2015-01 ,pp. : 5217-5222

Spandidos Publications

Access to resources Recommend Favorite

MACC1 induces metastasis in ovarian carcinoma by upregulating hepatocyte growth factor receptor cMET

By                  

Oncology Letters, Vol. 8, Iss. 2, 2014-01 ,pp. : 891-897

Spandidos Publications

Access to resources Recommend Favorite